Noxopharm Ltd - ESG Rating & Company Profile powered by AI
This Disclosure score includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Climate Action' and 'Peace, Justice & Strong Institutions'. The webpage of Noxopharm Ltd was assembled by All Street Sevva using cutting edge Cognitive Robots. The page displays a zero-cost ESG analysis for Noxopharm Ltd.
Noxopharm Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 5.3, social score of 3.2 and governance score of 4.0.
4.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 951 | Purple Biotech Ltd | 4.3 | High |
| 951 | Vectura Group Services Ltd | 4.3 | High |
| 969 | Noxopharm Ltd | 4.2 | High |
| 969 | Botanix Pharmaceuticals Ltd | 4.2 | High |
| 969 | Arvinas Inc | 4.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Noxopharm Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Noxopharm Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Noxopharm Ltd report the average age of the workforce?
Sign up for free to unlockDoes Noxopharm Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Noxopharm Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Noxopharm Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Noxopharm Ltd offer flexible work?
Sign up for free to unlockDoes Noxopharm Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Noxopharm Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Noxopharm Ltd conduct supply chain audits?
Sign up for free to unlockDoes Noxopharm Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Noxopharm Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Noxopharm Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Noxopharm Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Noxopharm Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Noxopharm Ltd disclose water use targets?
Sign up for free to unlockDoes Noxopharm Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Noxopharm Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Noxopharm Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Noxopharm Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Noxopharm Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Noxopharm Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Noxopharm Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Noxopharm Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Noxopharm Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Noxopharm Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Noxopharm Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Noxopharm Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Noxopharm Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Noxopharm Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Noxopharm Ltd disclose its waste policy?
Sign up for free to unlockDoes Noxopharm Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Noxopharm Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Noxopharm Ltd disclose energy use targets?
Sign up for free to unlockDoes Noxopharm Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Noxopharm Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Noxopharm Ltd
These potential risks are based on the size, segment and geographies of the company.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.